Inspire Medical Systems Shareholders Urged to Act Before Final Securities Fraud Deadline

Leading international law firm Bleichmar Fonti & Auld LLP has issued a reminder to investors in Inspire Medical Systems, Inc. (NYSE: INSP) about the ongoing securities fraud class action lawsuit and the final deadline to participate. The lawsuit claims that Inspire and certain senior executives violated federal securities laws following a significant drop in the company’s stock price, allegedly due to misleading statements about its business and product rollout. The complaint, filed in the U.S. District Court for the District of Minnesota under City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who acquired Inspire stock. Investors have until January 5, 2026 to ask the court to be appointed as lead plaintiff in the case. Inspire, known for its implantable devices for sleep apnea treatment—particularly the Inspire V—had repeatedly assured the market it was ready for a successful product launch. Prosecutors allege the company failed to prepare clinicians and insurers adequately, leading to delays and weaker-than-expected demand, which precipitated a more than 30% drop in stock value in August 2025. Affected shareholders are encouraged to visit the law firm’s case page for more information and to consider submitting a claim. Representation is on a contingency fee basis, with no upfront costs for investors. #InspireMedical #SecuritiesFraud #ClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM